Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.23.15 (renin)
 35,795 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a field study comprising 678 patients with arterial hypertension efficacy and tolerance of the stable combination VKB 105 consisting of 10 mg Pindolol (Visken) and 5 mg Clopamid (Brinaldix) were investigated. Treatment with 1--2 tablets of VKB per day resulted in a successful therapy in 94% of all patients corresponding on the average to a reduction in blood pressure to 145/85 mm Hg within 14 days. In mean arterial pressures ranging between 120 and 170 mm Hg a positive linear relationship between the individual initial value and the hypotensive effect of the combination could be observed. A controlled omission trial disclosed qualitatively the respective contribution to the effect of the two components Pindolol and Clopamid. With a systematic case control of the serum potassium under the combined therapy with VKB 105 and during a monotherapy with Clopamid and antihypokalaemic effect of Pindolol could be demonstrated diminishing the tendency for potassium loss. The result revealed a far-reaching potassium neutrality of diuresis-depending stimulation of renin by the beta-receptor blocker. In 61 patients altogether subjective side-effects could be recorded, such as vertigo (5%), palpitations (2.8%), fatigue (2%), insomina (1.9%), nausea (1.7%) and vomiting (0.8%). Laboratory controls gave no indication for clinically relevant changes.
 ...
PMID:[A field study with the combination of Pindolol and Clopamid in antihpertensive therapy (author's transl)]. 3 34

The condition of the sympatheticoadrenal system and blood renin activity were studied in healthy children and in children suffering from primary arterial hypertension and treated with beta-blocking agents (Obzidan, Visken). A hypotensive effect was noted in the group of patients suffering from primary arterial hypertension with a high blood renin level and increased excretion of catecholamines in the urine.
 ...
PMID:[State of the sympathetic-adrenal system and renin activity in the blood in children with primary arterial hypertension in the process of beta-blockader treatment]. 3 7

1. In 20 of 20 patients (100%) with borderline hypertension Visken normalized the labile blood pressure. The high renin values after stimulation due to orthostasis and saluresis decreased significantly (p less than 0,01). 2. In 3 of 12 patients (25%) with hyporeninemic essential hypertension Visken alone normalized the blood pressure. The low renin values increased to the normal range. 3. In 4 of 18 patients (22%) with normoreninemic essential hypertension Visken normalized the blood pressure. The normal renin values showed a decreasing tendency within the normal range. 4. In 4 of 10 patients (40%) with hyperreninemic essential hypertension Visken normalized the high blood pressure. In 3 of these patients renin decreased distinctly. 5. In 4 of 20 patients (20%) with renal hypertension a therapy with Visken alone normalized the blood pressure. In 3 patients the high renin values decreased to the normal range. 6. In the most other patients of the groups II to V the additional therapy with diuretics and reserpine normalized the blood pressure. In these cases the renin values showed different reactions corresponding to the different effects of betablocking agents, saluretics or reserpine on the plasma renin activity [7]. 7. It is interesting, that Visken not only suppresses high renin values (borderline hypertension [6], hyperreninemic essential hypertension), but also increases low renin values to the normal range in patients with hyporeninemic essential hypertension. Because in essential hypertension the high blood pressure per se may be responsible for the renin suppression [3,4], this increase of renin activity is possibly the consequence of blood pressure reduction, while the decrease of renin activity after Visken may be the cause of blood pressure reduction.
 ...
PMID:[Effect of pindolol (Visken) on blood pressure and plasma renin activity in various forms of hypertension]. 103 71

Using microcatheter blood pressure telemetry, the pressure-lowering effect of prindolol (Visken), a beta-blocking drug, was tested at a dose of 10 mg three time daily by mouth in eight patients with essential hypertension (WHO stage II) and low to normal plasma-renin activities. After about ten days of treatment, the hypertensive reaction to everyday physical exercise (walking, climbing stairs, bicycle ergometry) was especially favourably affected. The average blood-pressure reduction at rest was 18.6/12.1 (systolic/diastolic), on stair climbing 41.5/17.2 mm Hg.
 ...
PMID:[The effect of prindolol on the blood-pressure profile of hypertensives (with special consideration of response to exercise and plasma-renin activity) (author's transl)]. 115 70

Effect of three-week treatment with visken on renal and central haemodynamics, renin-angiotensin-aldosterone system (RAAS) and metabolism of electrolytes was studied in 88 elderly and old patients 45 of whom had hypertonic disease (HD) in the second stage and 43 suffered from atherosclerotic (isolated systolic) hypertension (AH). Visken is a highly effective hypotensive beta-adrenoblocker with partially retained sympathomimetic activity. It may be administered as monotherapy to elderly patients with HD as well as to the old and elderly with SH regardless of initial state of systemic and renal haemodynamics. The drug makes blood pressure fall due to its diuretic effect and decrease of general peripheral vascular resistance. It improves renal blood circulation, reduces renal vascular resistance, enhances compromised glomerular filtration but exert no influence upon RAAS. Efficacy of visken diminishes with age. This phenomenon is conditioned by increased refractivity rate and more frequent adverse effects in the old with HD. Latent heart failure, disorders of cardiac rhythm and conductivity (even if mentioned in anamnesis) as well as hypokalemia are contraindications to visken.
 ...
PMID:[The characteristics of using visken in middle-aged and elderly patients with arterial hypertension]. 803 Mar 4